Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rose by 1.7% in the past week and 0.34% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.78% and the outperformance increases to 6.14% for the last 4 weeks.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has received a short term rating of buy from research analysts at Zacks with a rank of 2. The company has been rated an average of 2 by 2 Wall Street Analysts.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has witnessed a rise of 2.6% or 60,625 shares in its short figure. The short interest augmentation took it from 2,370,409 on July 31,2015 to 2,431,034 on August 14,2015.
This report provides comprehensive information on the current therapeutic developmental pipeline of Rigel Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), ...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) will collaborate for the finding, marketing, and development of cancer immunotherapies with Bristol-Myers Squibb Co (NYSE:BMY), according to a press release reported on Monday.